www.live-criket-score.com,"Among outpatients with SARS-CoV-2 infection, treatment with a single dose of oral azithromycin compared with placebo did not result in a greater likelihood of being free of symptoms at day 14," the authors wrote in the study.
The researchers from the University of California, San Francisco (UCSF), and Stanford University randomly selected 171 candidates and induced 1.2 gm of Azithromycin in the form of an oral dose. On the other hand, a sum of 92 participants received an identical placebo. As a result, as many as 50 percent of the participants remained symptom-free until the 14th day. Nevertheless, on the 21st day, 5 out of the 171 candidates had to be hospitalised with severe symptoms of COVID-19.,cricket-identification-key
The treatment with a single Azithromycin dose, when compared to its identical counterpart, produced no better result than a placebo. "These findings do not support the routine use of azithromycin for the outpatients of SARS-CoV-2 infection," said the lead author of the study, Catherine E. Oldenburg, an assistant professor at UCSF. Even though the hypothesis suggested that an oral dose of Azithromycin contained anti-inflammatory properties to prevent the progression of the COVID-19 disease, the study published in the journal informed otherwise, Oldenburg concluded. ,fantasy-cricket-app-developmentkpr-full-form